Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities
- PMID: 37749246
- DOI: 10.1038/s41588-023-01515-7
Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities
Erratum in
-
Author Correction: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities.Nat Genet. 2024 Mar;56(3):553. doi: 10.1038/s41588-024-01680-3. Nat Genet. 2024. PMID: 38396071 No abstract available.
Abstract
The paradigm of cancer-targeted therapies has focused largely on inhibition of critical pathways in cancer. Conversely, conditional activation of signaling pathways as a new source of selective cancer vulnerabilities has not been deeply characterized. In this study, we sought to systematically identify context-specific gene-activation-induced lethalities in cancer. To this end, we developed a method for gain-of-function genetic perturbations simultaneously across ~500 barcoded cancer cell lines. Using this approach, we queried the pan-cancer vulnerability landscape upon activating ten key pathway nodes, revealing selective activation dependencies of MAPK and PI3K pathways associated with specific biomarkers. Notably, we discovered new pathway hyperactivation dependencies in subsets of APC-mutant colorectal cancers where further activation of the WNT pathway by APC knockdown or direct β-catenin overexpression led to robust antitumor effects in xenograft and patient-derived organoid models. Together, this study reveals a new class of conditional gene-activation dependencies in cancer.
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Comment in
-
Hyperactivation of oncogenic driver pathways as a precision therapeutic strategy.Nat Genet. 2023 Oct;55(10):1613-1614. doi: 10.1038/s41588-023-01493-w. Nat Genet. 2023. PMID: 37749245 No abstract available.
Similar articles
-
Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling.Clin Cancer Res. 2017 Dec 1;23(23):7340-7350. doi: 10.1158/1078-0432.CCR-17-0749. Epub 2017 Sep 22. Clin Cancer Res. 2017. PMID: 28939743
-
TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.Gastroenterology. 2019 Feb;156(3):708-721.e15. doi: 10.1053/j.gastro.2018.10.031. Epub 2018 Oct 24. Gastroenterology. 2019. PMID: 30365932
-
Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29. Clin Cancer Res. 2016. PMID: 26224873
-
The research progress of Wnt/β-catenin signaling pathway in colorectal cancer.Clin Res Hepatol Gastroenterol. 2023 Mar;47(3):102086. doi: 10.1016/j.clinre.2023.102086. Epub 2023 Jan 16. Clin Res Hepatol Gastroenterol. 2023. PMID: 36657523 Review.
-
The mechanisms of class 1A PI3K and Wnt/β-catenin coupled signaling in breast cancer.Biochem Soc Trans. 2023 Aug 31;51(4):1459-1472. doi: 10.1042/BST20220866. Biochem Soc Trans. 2023. PMID: 37471270 Free PMC article. Review.
Cited by
-
ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway.Cancer Res Commun. 2024 Oct 1;4(10):2734-2755. doi: 10.1158/2767-9764.CRC-24-0268. Cancer Res Commun. 2024. PMID: 39324706 Free PMC article.
-
Hyperactivation of oncogenic driver pathways as a precision therapeutic strategy.Nat Genet. 2023 Oct;55(10):1613-1614. doi: 10.1038/s41588-023-01493-w. Nat Genet. 2023. PMID: 37749245 No abstract available.
-
Perspectives on cancer therapy-synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges.Cell Death Discov. 2025 Apr 16;11(1):179. doi: 10.1038/s41420-025-02418-8. Cell Death Discov. 2025. PMID: 40240755 Free PMC article. Review.
-
Understanding the Toxicity Profile of Approved ADCs.Pharmaceutics. 2025 Feb 14;17(2):258. doi: 10.3390/pharmaceutics17020258. Pharmaceutics. 2025. PMID: 40006625 Free PMC article.
-
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.Nat Commun. 2025 Jul 8;16(1):6270. doi: 10.1038/s41467-025-60884-1. Nat Commun. 2025. PMID: 40623967 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases